DGAT1 Inhibition for Opioid-Induced Constipation Relief
Solution Overview
Problem
Current treatments for opioid-induced constipation (OIC) are often ineffective and associated with significant side effects, highlighting a need for a more effective and side-effect-minimized therapeutic approach.
Innovation Solution
Administration of a therapeutically effective amount of a DGAT1 inhibitor to reduce symptoms of gastrointestinal dysfunction, specifically constipation, by targeting the enzyme diacylglycerol acyltransferase 1 involved in triglyceride biosynthesis in the gut.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If typical constipation treatments (bulk-forming laxatives, increased fiber) are used, then bowel movement frequency may increase, but they can cause bowel obstruction and worsen fecal impaction
Solution Approach 1:
The patent changes the biochemical parameters of fecal material by inhibiting DGAT1 enzyme activity, thereby reducing triglyceride content and altering fecal composition. This biochemical parameter change prevents the mechanical obstruction issues associated with bulk-forming laxatives while still promoting bowel movements.
Solution Approach 2:
The patent replaces mechanical bulk-forming laxatives with a biochemical enzyme inhibitor approach. Instead of adding physical bulk to stool, the DGAT1 inhibitor works at the molecular level to change fecal composition and consistency, eliminating the mechanical obstruction risk.
2Speed
If stimulant laxatives are used, then bowel propulsion increases, but they cause bowel irritation due to overly dry fecal material
Solution Approach 1:
The patent changes the physical-chemical parameters of fecal material by reducing triglyceride content through DGAT1 inhibition. This results in softer, more pliable feces that can be propelled without causing irritation, replacing the harsh mechanical stimulation of stimulant laxatives with a gentler biochemical modification.
3Ease of operation
If Mineral oil is used, then stool softening occurs, but it decreases absorption of fat-soluble vitamins A, D, E, and K
Solution Approach 1:
Instead of using mineral oil to soften stool (which causes vitamin loss), the patent targets the harmful triglyceride component directly through DGAT1 inhibition. By reducing the problematic substance (triglycerides) at its source of synthesis, the patent achieves stool softening without the harmful side effects of mineral oil.
4Productivity
If osmotic laxatives are used, then bowel movement frequency increases, but they cause electrolyte abnormalities and require rectal administration
Solution Approach 1:
The patent replaces the osmotic mechanism (which disrupts electrolyte balance) with a targeted enzymatic inhibition approach. By specifically blocking DGAT1 activity in the intestine, the patent achieves bowel movement promotion through localized biochemical action rather than systemic osmotic effects, avoiding electrolyte disturbances.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of DGAT1 inhibitors significantly reduces symptoms of constipation, including fecal pellet output and weight, demonstrating efficacy in treating opioid-induced constipation with minimal side effects.
Implementation Method 1
DGAT1 (diacylglycerol acyltransferase 1) is an enzyme associated with triglyceride biosynthesis in the gut, liver and adipose tissue
Data Source
AI summary
The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.